解惑AD | 人们应该知道的 “ 关于特应性皮炎的10个件事

提高特应性皮炎对患者及其家属影响的认识

不仅仅是“皮疹”

特应性皮炎不仅是一种“皮疹”，它是一种慢性免疫介导的疾病，是全身性的、无法治愈的，在皮肤上可见，严重影响患者的生活质量。^[1,2]

患病率

特应性皮炎的全球患病率差异很大，据报道，儿童患者的患病率在5%-20%之间^[3,4] ，估计10%-40%的AD患儿为中重度。^[4-11]

全世界范围内，2–10%的成人受到特应性皮炎的影响^[12]，其中重度特应性皮炎的成人患者占2%-8%。^[13]

我国1-7岁儿童特应性皮炎的患病率为12.94%，其中，23.97%为中度，1.44%为重度。^[14]

成人期&儿童期起病

特应性皮炎在不同的起病年龄和严重程度下，遵循可变的自然病程^[15]。虽然特应性皮炎可以在青春期后消退，但月30%的特应性皮炎患儿在成年后仍继续患病。15%-30%的成人特应性皮炎起病与成年期。^[16-21]

对皮肤的影响

中重度特应性皮炎的特征是身体大部分或敏感部位出现疼痛性病变，可覆盖超过50%的体表^[23]。症状包括剧烈瘙痒、皮肤干燥、开裂、发红、结痂和渗出^[22,23]。在搔痒处持续搔抓会损害皮肤，增加感染风险。^[23-25]

对身体健康的影响

高达72%的中重度特应性皮炎患者存在由共同的潜在炎症过程引发的其他特应性共病，包括：哮喘、鼻息肉、过敏性鼻炎、过敏性结膜炎、食物过敏和慢性鼻窦炎。^[26]

对心理健康的影响

由于特应性皮炎的可见症状和病变通常出现在手和脸上，许多特应性皮炎成人患者会感到尴尬和自卑，经常会逃避工作和社交^[1,27,28]。在一项已发表的研究中，约40%的青少年和1/4的儿童特应性皮炎患者因患病而遭受欺凌，并且这两个年龄组的患者中均有一半感到不快乐或抑郁^[27]。

对社会的影响

特应性皮炎患者的睡眠紊乱会导致疲劳和日间功能受损^[29]，包括工作表现^[30,31]。特应性皮炎患者报告说，发病期间10%的工作表现会受到影响，平均旷工2.7天^[27] 。特应性皮炎儿童患者的学习成绩也会由于旷课而受到影响^{[27,28,32,33]}。特应性皮炎控制不良给患者、家庭和整个社会都带来了经济负担。随着疾病严重程度的增加，经济负担也随之增加。^[30,34-36]

现在治疗选择

目前特应性皮炎的管理策略包括恢复皮肤屏障、对症治疗、减少疾病恶化次数、严重程度和持续时间，同时尽量减少治疗相关的不良反应^[24,37]。当局部治疗控制不良时，患者需采用系统治疗^[18]。系统性使用免疫抑制剂通常是超说明书使用，且会导致广泛的免疫抑制。这些和口服糖皮质激素一样，都有潜在的副作用，可能会限制其长期使用。^[38-41]

未满足的额外选择需求

许多中重度特应性皮炎患者报告说，即使使用了局部和/或系统性治疗，仍有严重瘙痒和体征及症状加重，这表明仍需要额外的治疗选择。^[42-46]

达到最佳控制

新的治疗方案旨在为控制不良的特应性皮炎患者带来更有针对性的长期系统性治疗方案。^[47]

# 参考文献 #

[1] E. Simpson, T. Bieber and L. Eckert, “Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b on clinical trial of dupilumab in adults,” Am Acad Dermatol, vol. 74, no. 3, pp. 491-498, 2016; [2] D. Leung, R. Nicklas and J. Li, “Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters,” Ann Allergy Asthma Immunol, vol. 93, no. 3 (Suppl. 2), pp. S1-S21, 2004; [3] T.E. Shaw, G.P. Currie, C.W. Koudelka, E.L. Simpson, “Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health”, J Invest Dermatol, vol. 131, no. 1, pp. 67-73, 2011; [4] H. Williams, C. Robertson, A. Stewart, et al. “Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood”, J Allergy Clin Immunol, vol. 103, no 1, pp. 125-138, 1999; [5] N. Ballardini, I. Kull, C. Soderhall, G. Lilja, M. Wickman, C.F. Wahlgren, “Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort”, Br J Dermatol, vol. 168, no. 3, pp. 588-594, 2013; [6] S.J. Brown, C.L. Relton, H. Liao, et al., “Filaggrin null mutations and childhood atopic eczema: a population-based case-control study”. J Allergy Clin Immunol, vol. 121, no. 4, pp. 940-946, 2008; [7] S. Dhami, A. Sheikh, “Estimating the prevalence of aero-allergy and/or food allergy in infants, children and young people with moderate-to-severe atopic eczema/dermatitis in primary care: multi-centre, cross- sectional study”, J R Soc Med, vol. 108, no. 6, pp. 229-236, 2015; [8] A. Lebon, J.A. Labout, H.A. Verbrugh, et al., “Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study”. Arch Pediatr Adolesc Med., vol. 163, no. 8, pp. 745-749, 2009; [9] A.B. Olesen, K. Bang, S. Juul, K. Thestrup-Pedersen, “Stable incidence of atopic dermatitis among children in Denmark during the 1990s”, Acta Derm Venereol, vol 85, no. 3, pp. 244-247, 2005; [10] H. Saeki, H. Iizuka, Y. Mori, et al. “Prevalence of atopic dermatitis in Japanese elementary schoolchildren”, Br J Dermatol, vol. 152, no. 1., pp. 110-114, 2005; [11] J.I. Silverberg, E.L. Simpson, “Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization”, Pediatr Allergy Immunol, vol. 24, no. 5, pp.476-486, 2013; [12] World Allergy Organization, “White book on allergy: update 2013,” 2013. [Online]. Available: http://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf. [Accessed 24 July 2017]; [13] S. Barbarot, S. Auziere, A. Gadkari, G. Girolomoni, L. Puig, E. L. Simpson, D. J. Margolis, M. de Bruin-Weller, L. Eckert, “Epidemiology of atopic dermatitis in adults: results from an international survey”, Allergy, vol. 73, no.6, pp. 1284-1293, 2018; [14] Guo, Y., et al., “Prevalence of Atopic Dermatitis in Chinese Children aged 1-7 ys”. Scientific reports, vol. 6: pp. 29751, 2016; [15] T. Bieber, “Personalized management of atopic dermatitis: beyond emollients and topical steroids”. In: T. B, F. N, eds. “Personalized treatment options in dermatology”, Springer-Verlag, pp. 61-76, 2015; [16] T. Bieber, “Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine,” Allergy, vol. 67, no. 12, pp. 1475-1482, 2012; [17] D. Garmhausen, T. Hagemann and T. Bieber, “Characterization of different courses of atopic dermatitis in adolescent and adult patients,” Allergy, vol. 68, no. 4, pp. 498-506, 2013; [18] L. Eichenfield, W. Tom and S. Chamlin, “Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis,” J Am Acad Dermatol, vol. 70, no. 2, pp. 338-351, 2014; [19] T. Bieber, “Atopic dermatitis, Mechanisms of Disease,” N Engl J Med, vol. 358, no. 14, pp. 1483-1494, 2008; [20] E. Guttman-Yassky, K. Nograles and J. Krueger, “Contrasting pathogenesis of atopic dermatitis and psoriasis–part I: clinical and pathologic concepts,” J Allergy Clin Immunol, vol. 127, no. 5, pp. 1110-1118, 2011; [21] A. Blauvelt, M. de Bruin-Weller and M. Gooderham M (2017). Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, 389(10086), pp. 2287-2303; [22] K. Eyerich, S. Eyerich and T. Biedermann, “The Multi-Modal Immune Pathogenesis of Atopic Eczema,” Trends Immunol, vol. 36, no. 12, pp. 788-801, 2015; [23] C. Correale, C. Walker and L. Murphy, “Atopic dermatitis: a review of diagnosis and treatment,” Am Fam Physician, vol. 60, no. 4, pp. 1191-1198, 1999; [24] J. Ring, A. Alomar and T. Bieber, “Guidelines for treatment of atopic eczema (atopic dermatitis) Part I,” J Eur Acad Dermatol Venereol, vol. 26, no. 8, pp. 1045-1060, 2012; [25] E. Simpson, “Comorbidity in Atopic Dermatitis,” Curr Dermatol Rep, vol. 1, no. 1, pp. 29-38, 2012; [26] E. Simpson, E. Guttman-Yassky, D. J Margolis et al (2016). Chronicity, Comorbidity and Life Course Impairment in Atopic Dermatitis: Insights from a Cross-Sectional Study in US Adults. Poster P0301 presented at 25th EADV; (September 28–October 2, 2016, Vienna, Austria); [27] T. Zuberbier, S. Orlow and A. Paller, “Patient perspectives on the management of atopic dermatitis,” J Allergy Clin Immunol, vol. 118, no. 1, pp. 226-232, 2006; [28] A. Torrelo, J. Ortiz and A. Alomar, “Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management,” Eur J Dermatol, vol. 22, no. 4, pp. 97-105, 2012; [29] J. Schmitt, F. Csotonyi, A. Bauer and M. Meurer, “Determinants of treatment goals and satisfaction of patients with atopic eczema,” J Dtsch Dermatol Ges, vol. 6, no. 6, pp. 458-465, 2008; [30] W. Wei, A. Gadkari and R. Klumph, “Burden of disease among employees with atopic dermatitis: comorbidities, healthcare resource utilization/costs, and absenteeism (abstract LO2),” J Manag Care Spec Pharm, vol. 21, no. 10-a, pp. S64-S65, 2015; [31] E. Holm, S. Esmann and G. Jemec, “The handicap caused by atopic dermatitis – sick leave and job avoidance,” J Eur Acad Dermatol Venereol, vol. 20, no. 3, p. 255–259, 2006; [32] E.E. Brenninkmeijer, C.M. Legierse, J.H. Sillevis Smitt, B.F. Last, M.A. Grootenhuis, J.D. Bos, “The course of life of patients with childhood atopic dermatitis,” Pediatr Dermatol, vol. 26, no. 1, p.14-22, 2009; [33] M. Boguniewicz, et al., “A multiple-domain framework of clinical, economic, and patient- reported outcomes for evaluating benefits of interverntion in atopic dermatitis,” J Drugs Dermatol, vol. 6, no. 4, p.416-423, 2007; [34] D. Fivenson, R. Arnold and D. Kaniecki, “The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization,” J Manag Care Pharm, vol. 8, no. 5, pp. 333-342, 2002; [35] S. M. Shrestha, L. Wang and J. Chao, “Burden of atopic dermatitis: comorbidities, healthcare resource utilization, and costs in US commercial and Medicare adult populations (abstract L02),” J Manag Care Spec Pharm, vol. 22, no. 10-a, p. S71, 2016; [36] S. Shrestha, R. Miao and L. Wang, “Burden of atopic dermatitis among adults in a State Medicaid Program (Medi-Cal) (abstract O059),” Ann Allergy Asthma Immunol, vol. 117, p. S19, 2016; [37] R. Law and P. Kwa, Atopic Dermatitis. Pharmacotherapy: A Pathophysiologic Approach, 9th ed., McGraw-Hill Education, 2014; [38] C. Akdis, M. Akdis and T. Bieber, “Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report,” J Allergy Clin Immunol, vol. 118, no. 1, pp. 152-169, 2006; [39] R. Sidbury, D. Davis and D. Cohen, “Guidelines of care for the management of atopic dermatitis. Part 3: Management and treatment with phototherapy and systemic agents,” J Am Acad Dermatol, vol. 71, no. 2, pp. 327-349, 2014; [40] T. Bieber and B. Straeter, “Off-label prescriptions for atopic dermatitis in Europe,” Allergy, vol. 70, no. 1, pp. 6-11, 2015; [41] H. Saeki, T. Nakahara and A. Tanaka, “Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016,” J Dermatol, vol. 43, no. 10, pp. 1117-1145, 2016; [42] S. Meggitt, J. Gray and N. Reynolds, “Azathioprine dosed by thiopurine methyltransferase activity for moderate to severe atopic eczema: a double-blind, randomised controlled trial,” Lancet, vol. 367, no. 9513, pp. 839-846, 2006; [43] D. Ashcroft, P. Dimmock and R. Garside, “Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta- analysis of randomized controlled trials,” BMJ, vol. 330, no. 7490, pp. 516-522, 2005; [44] J. Schmitt, K. Schakel and N. Schmitt, “Systemic treatment of severe atopic eczema: a systematic review,” Acta Derm Venereol, vol. 87, no. 2, p. 100–111, 2007; [45] J. Kim, J. Shin and J. Ko, “Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine,” Dermatol Ther, vol. 29, no. 2, p. 120–125, 2016; [46] M. Schram, E. Roekevisch and M. Leeflang, “A randomized trial of methotrexate versus azathioprine for severe atopic eczema,” J Allergy Clin Immunol, vol. 128, no. 2, pp. 353-359, 2011; [47] E. Guttman-Yassky, N. Dhingra and D. Leung, “New Era of Biological Therapeutics in Atopic Dermatitis,” Expert Opin Biol Ther, vol. 13, no. 4, pp. 549-61, 2013.

MAT-CN-2108945

有效期：2023年5月28

发表评论 取消回复

发表评论取消回复